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INTERSTITIAL LUNG DISEASES: ALGORITHM,
TREATMENT AND FOLLOW-UP
Davor Jurman
Department of Pulmonology, Sestre milosrdnice University Hospital, Zagreb, Croatia
SUMMARY ∑ Interstitial lung diseases and related difficulties that a clinician encounters in daily
practice are presented. The disease may be of known origin, such as postirradiation pneumonitis,
pneumoconioses, allergic alveolitis, etc., or of unascertainable origin, such as sarcoidosis and sys-
temic diseases with multiple organ involvement, e.g., Goodpasture’s syndrome. In the article, par-
ticular reference is made to sarcoidosis and cryptogenic fibrosing alveolitis. Interstitial diseases are
still classified and referred to as (abbrev.) UIP, NSIP, DIP, LIP, BOOP and AIP. Both AIP and UIP
are considered to have poor prognosis. This is a modification of Liebow’s classification. The World
Association of Sarcoidosis and Other Granulomatous Disorders has proposed guidelines for the fol-
low-up of patients with these diseases. The recommended methods include bronchoalveolar lavage,
angiotensin-converting enzyme determination, gallium scan (of the whole body or of the lungs), and
high-resolution computed tomography. These parameters, along with clinical evaluation, and immu-
nologic and functional tests, should prove adequate in most cases, while the rest of unresolved cases
should be considered for either bronchoscopic transbronchial or surgical (thoracoscopic or open lung)
biopsy. Most of our patients were treated with steroids, and only some 25% of them improved with-
out this therapy. The patients treated with steroids responded to treatment without major side ef-
fects, with the exception of two patients who failed to respond favorably to this therapy. One of these
two patients, however, had to be treated with low-dose steroids for more than ten years. New meth-
ods such as high-resolution computed tomography, along with the established ones such as gallium
scan, help in the diagnosis of early stages of interstitial involvement, so that steroid therapy can be
initiated on time, which is of crucial importance for prevention of the disease progression to the
irreversible fibrotic stage. Prospective trials are needed to find new diagnostic and therapeutic meth-
ods based on novel concepts on the disease etiology.
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Differential diagnosis of diseases manifesting with
proliferation of the pulmonary interstitium belongs to the
most difficult fields not only in pulmonology but in gen-
eral medicine as a whole. Normally, the interstitium
should not be visible on a lung x-ray, and if seen, it points
to pathologic changes due to viral or mycoplasma induced
pneumonia. Cardiac decompensation, noncardiogenic
pulmonary edema (acute respiratory disease syndrome or
acute pulmonary lesions) of unknown etiology (e.g., sar-
coidosis), systemic disease with multiple organ involve-
ment (e.g., Goodpasture’s syndrome), miliary tuberculo-
sis, occupational diseases (pneumoconioses, allergic
alveolitis), or therapy induced alveolitis (e.g., Cordarone,
bleomycin, TCT, actinotherapy) are states and syndromes
that should be considered, recognized, properly treated,
or possibly even prevented.
The interstitial pattern may be finely reticular, micro-
nodular or macronodular, while in case of the alveolitis
progression to fibrosis a frosted-glass shadow or honey-
comb lung may develop.
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Cryptogenic fibrosing alveolitis or idiopathic pulmo-
nary fibrosis is a disease of unknown etiology. A variety
of criteria have been used for its classification, e.g., patho-
anatomical, radiological, clinical, etc. According to recent
concepts, there are pathologic changes of the interstitium
as part of a syndrome, e.g., common interstitial pneumo-
nia (UIP), desquamative interstitial pneumonia (DIP) or
RBILD, acute interstitial pneumonia (AIP), nonspecific
interstitial pneumonia (NSIP), giant cell interstitial pneu-
monia (GCIP) and lymphoid interstitial pneumonia
(LIP), as modifications of the original classification ac-
cording to Liebow.
The classification depends on the pathohistologic fin-
ding, while the material obtained by bronchoscopy and
transbronchial biopsy may not always be representative
enough for the cytologic or pathoanatomical diagnostic
criteria. Therefore, attempts are made to reach an accu-
rate diagnosis in an indirect and noninvasive way in or-
der to initiate appropriate therapy on time, thus to pre-
vent the progression of alveolitis to irreversible pulmonary
fibrosis; and that is why the abbreviation for interstitial
pulmonary fibrosis (IPF) should be distinguished from the
abbreviation for interstitial lung disease (ILD).
Besides nonspecific symptoms, which need not always
be present, the major symptom is shortness of breath on
exertion, accompanied by dry cough (patients frequently
describe inappetence, arthralgia and dry cough as a ‘flu’
or postvirosis state). Hematologic, bacteriologic and se-
rologic tests should be routinely performed. In case of
multiple organ system involvement, functional tests of the
liver, brain and kidneys, immunologic assays, and rheu-
matologic factor determination should also be performed.
In case of interstitial pattern persisting after macrolide
therapy, additional target testing should include respira-
tory function (restrictive ventilation impairment is fre-
quently observed), supplemented by diffusion; gallium
scintigraphy of the lungs or whole body; high-resolution
computed tomography (CT); and bronchoalveolar lavage
and/or transbronchial lung biopsy by bronchofibroscopy.
In addition to other parameters, mention should be
made of the activity of the angiotensin converting enzyme
(ACE), which is usually increased in sarcoidosis (stage 2)
and points to granulomas still being formed in the lungs,
indicating the activity of macrophages and T lymphocytes.
May all these parameters fail to result in timely and
accurate diagnosis, while the disease continues to progress
or no remission occurs, lung biopsy (open or during tho-
racoscopy) is performed in consultation with a thoracic
surgeon and with patient’s consent. This procedure pro-
vides an adequate, representative sample of the pulmonary
tissue which will not reveal the etiology of disease, but will
provide relevant information to justify the introduction of
corticosteroid therapy (UIP and AIP have poorer prog-
nosis than other interstitial diseases). The initial dose is
1 mg per kg body weight, and therapy should be admin-
istered for at least one year (except in case of negative find-
ing of bronchoalveolar lavage in stage 1 sarcoidosis, i.e. in
the stage of bihilar adenopathy, when spontaneous remis-
sion of the disease is expected to occur). Frequent controls,
monitoring and management of side effects are necessary.
In case of steroid intolerance or failure, alternative therapy
includes cyclophosphamide, azathioprine, methotrexate,
and colchicine, while the role of thalidomide and pento-
xifylline is controversial. Before therapy introduction,
gallium scintigraphy of the lungs or whole body and high-
resolution CT should be performed to allow for subse-
quent follow-up of disease remission and assessment of
therapeutic success.
Follow-up of the course of disease and treatment suc-
cess includes lung x-ray, respiratory function assessment,
and ACE determination at 1- to 2-month intervals in case
of sarcoidosis. Bronchoalveolar lavage is not suitable for
the purpose of follow-up. The criteria of severe alveolitis
include lymphocyte predominance in bronchoalveolar
lavage (cytology) and immunologic parameters, i.e. high
percentage of T lymphocytes (>28%) and a T lymphocyte
CD4:CD8 subpopulation ratio exceeding 3.5.
Sarcoidosis is a disease of unknown cause, with char-
acteristic granuloma formation. Activated T lymphocytes
and macrophages accumulate in granulomas, which may
affect multiple organs (besides lungs and mediastinal
lymph nodes, the liver, salivary glands, pericardium and
central nervous system may also be involved). Unfortu-
nately, specific antigens that trigger the cascade of im-
mune events have not yet been identified. A combination
of environmental effects and genetic predisposition lead-
ing to the multisystem disease has been speculated, how-
ever, from the view of a clinician there is no substantial
difference in therapeutic approach in idiopathic pulmo-
nary disease (alveolitis partially transforming to fibrosis)
and stage 2 sarcoidosis.
High-resolution CT is of great value in detecting ini-
tial stage 2 disease that requires rapid diagnosis and the-
rapy, because interstitital lesions can hardly be observed
on lung x-ray, while regular CT cannot visualize granu-
lomas in the stage of formation.
Among patients with sarcoidosis who had been regu-
larly followed-up for several years, only three patients were
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not prescribed corticosteroid therapy (initial stage of ad-
enopathy, spontaneous disease regression). In the remain-
ing patients, 12-month corticosteroid therapy proved ef-
ficacious, with uncomplicated course of disease and with-
out major side effects. In two patients, the steroid dose
had to be tapered at a faster rate due to adiposity and hy-
pertension, which resulted in relapse of the disease neces-
sitating dosage increase and prolonged therapy (18
months). In one patient, cyclophosphamide was intro-
duced because of steroid therapy failure and intolerance.
This secondary therapy was well tolerated by the patient
and resulted in disease subsidence, however, at a some-
what slower rate. Two highly complicated cases included
a patient with multisystem involvement (salivary glands,
giving rise to suspicion of neurosarcoidosis). The dilemma
has not yet been solved, and the patient has been submit-
ted to additional studies. Steroid therapy was adminis-
tered for about two years, and the patient reported po-
lyarthralgias upon its discontinuation. In the other, female
patient, therapy with low-dose steroid was prescribed for
ten years because of multiorgan involvement, including
the liver, eyes and pericardium. High-dose therapy was
poorly tolerated by the patient, however, low-dose steroid
therapy could not be discontinued because any attempt at
corticosteroid administration only in the form of Becotide
spray as a substitute for the maintenance dose failed.
Uncomplicated course of the disease was recorded in
not more than some 25% of cases. We believe that con-
trol lung x-rays and ACE determination should be regu-
larly performed at 1- to 2-month intervals in patients with
verified sarcoidosis. Such a schedule should prove appro-
priate in patients with uncomplicated course of the dis-
ease. In case of poor therapeutic effect or failure (even
with increased ACE without signs of lung disease exac-
erbation), gallium scintigraphy of the whole body should
be performed at one-year intervals, whereas high-resolu-
tion CT should also be done at 6- to 12-month intervals
in complicated cases. The follow-up of therapeutic suc-
cess does not require bronchoalveolar lavage, as generally
accepted worldwide.
It should be noted that a relatively small number of
sarcoidosis patients were analyzed, thus the course of their
disease could not be compared with other studies includ-
ing more patients. Nevertheless, we may have declared
some cases uncomplicated when other organs were also
involved, or when stage 2 of the disease could not have
yet been recognized, and gallium scintigraphy or high-
resolution CT was not performed (discrepancy between
a seemingly insignificant finding on lung x-ray, and gal-
lium scintigraphy or high-resolution CT is striking). Ac-
cordingly, none of the currently used methods can replace
another one, but all these valuable methods should be con-
sidered complementary. Future prospective studies will
hopefully result in novel concepts on these peculiar dis-
eases that usually affect young people who develop acute
states and syndromes which, if proceeding unrecognized,
may even lead to lethal outcome unless the cascade of
unfavorable events in the body being timely interrupted
by appropriate therapy. The World Association of Sarcoi-
dosis and Other Granulomatous Disorders has issued rec-
ommendations for the disease follow-up and assessment
of the disease activity, which include serum ACE, high-
resolution CT, gallium scintigraphy, and immunologic
bronchoalveolar lavage parameters (listed above). We tried
to use this follow-up algorithm even before we have
learned about this consensus, reached in 1993.
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Saæetak
ALGORITAM PRETRAGA KOD BOLESTI PLU∆NOG INTERSTICIJA
D. Jurman
Prikazana je diferencijalna dijagnoza bolesti s patologijom intersticija, od bolesti poznatoga uzroka (karcinomatozna
limfangioza, profesionalne bolesti, oπteÊenja pluÊa lijekovima ili zraËenjem i druge) do bolesti nepoznatog uzroka (kriptogeni
fibrozirajuÊi alveolitis, sarkoidoza) i autoimunih bolesti sa zahvaÊenjem viπe organa i pluÊa (Goodpastureov sindrom), koje
predstavljaju dijagnostiËki problem. Intersticijske bolesti mogu biti izraæene i u bolesti sa zahvaÊenjem drugih organa (poznatog
uzroka), npr. bubrega, jetre i srca. Upalne (virusne infekcije i infekcije mikoplazmom) i nasljedne bolesti takoer su spomenute.
Posebna je pozornost posveÊena kriptogenom fibrozirajuÊem alveolitisu i sarkoidozi, gdje uz rutinsku obradu treba provesti i
dodatne pretrage angiotenzin konvertaze, pluÊne funkcije s difuzijom, dok rendgenske pretrage valja dopuniti kompjutoriziranom
tomografijom visoke rezolucije. »esto je potrebno provesti i scintigrafiju pluÊa (ili cijelog tijela) galijem, a od invazivnih
pretraga treba provesti bronhoskopiju s transbronhijalnom biopsijom ili bronhoalveolarnu lavaæu s citoloπkom i imunoloπkom
analizom bronhoalveolarne lavaæe (znakoviti omjeri subpopulacija T limfocita pokazuju radi li se o teæem obliku alveolitisa).
Ako ni nakon svih ovih pretraga nije jasno o kojoj se bolesti radi, u dogovoru s kirurzima izvodi se biopsija pluÊa (torakoskopska
ili otvorena). Terapija kortikosteroidima nije bila potrebna u samo 25% bolesnika sa sarkoidozom, πto se donekle razlikuje od
podataka iz drugih klinika gdje je bio obuhvaÊen veÊi broj bolesnika. VeÊina je bolesnika uza steroidnu terapiju ipak pokazala
povoljan tijek, u dva od ukupno trinaest sluËajeva komplikacije su bile jaËe izraæene, dok jedna bolesnica od to dvoje mora
trajno veÊ preko deset godina uzimati kortikosteroide. U skladu s preporukama Svjetskog udruæenja za sarkoidozu i granulomatoze
treba, dakle, u poËetku bolesti uËiniti (i) bronhoalveolarnu lavaæu koja, meutim, nije pogodna za praÊenje terapijskog uËinka.
Kontrolni su pregledi potrebni u odreenim vremenskim razmacima. Uz angiotenzin konvertazu, treba provesti kontrolne
pretrage kompjutoriziranom tomografijom visoke rezolucije, scintigrafiju toraksa i cijelog tijela galijem (po potrebi u vremenu
kraÊem od πest mjeseci), imajuÊi pritom u vidu i cijene navedenih pretraga. Ovaj je algoritam na naπoj Klinici primjenjivan
i prije preporuka donesenih 1993. i 1994. godine. Potrebna su daljnja istraæivanja, kao i praÊenje ovih bolesnika, jer se radi
o bolesti koja pogaa mlae ljude (prosjeËna dob u naπih bolesnika bila je 30 godina), a kad se ne lijeËi, bolest prelazi u
ireverzibilnu fibrozu. Kompjutorska tomografija visoke rezolucije i scintigrafija galijem poglavito su pogodne metode za
dijagnosticiranje i praÊenje bolesti intersticija, jer se na rendgenskoj snimci pluÊa ne vidi intersticij u ranoj fazi (mreæolik), dok
obiËna kompjutorska tomografija ne razaznaje granulome u fazi njihova stvaranja.
KljuËne rijeËi: PluÊne bolesti, intersticijske, klasifikacija; PluÊne bolesti, intersticijske, dijagnostika; PluÊne bolesti, intersticijske,
terapija
